We are here to bridge the gap between you and your Doctor/Patient! Let us help educate the medical professionals you know. The Endocannabinoid System is fascinating and the scientific research is now starting to permeate the traditional medical community.
Raphael Mechoulam Ph.D., an Israeli scientist, is responsible for identifying the psychoactive cannabinoid, THC.
"......in 1963 and 1964. Our first paper was on the structure of cannabidiol, and a bit later we isolated for the first time THC in pure form and elucidated its structure.
It turns out there are about 100 compounds of the same type – we isolated most of the major ones, but they didn’t turn out to be psychoactive. The only one that was psychoactive was THC. The other compound, cannabidiol (CBD), is found at high levels in most cannabinoid mixtures. Most plants produce cannabidiol or its precursor. This compound turned out to be of extreme interest. We found a few years later, after a lot of preclinical work in rats and mice, that CBD had antiepileptic properties."
Dr. Mechoulam continued his studies and has a vast quantity of research published.
In the same vein, A.C. Howlett identified and classified receptors for the endocannabinoids in mammals. If you follow the link, you can see these receptors were found in the early 1980's, so scientist have been working hard to identify important information regarding the endocannabinoid system.
Dr. Mechoulam has stated that the NHS has published research indicating that the endocannabinoid system is implicated in all major disease processes in the human body. It's no wonder that this natural product has been reported to benefit many patients suffering from various aliments.
Essentially, the Endocannabinoid system consists of endocannabinoid receptors, their ligands, and receptors. These three elements work together to balance disease processes in the human body.